BRANFORD, Conn., Oct. 21, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that nine new scientific abstracts demonstrating the use of the Company's FORE-SIGHT® Absolute Oximeter were presented at the annual meeting of the American Society of Anesthesiologists (ASA) and at the annual meeting of the Society for Neuroscience in Anesthesiology and Critical Care (SNACC) this past week in San Diego, CA. These meetings draw over 13,000 anesthesiologists from around the world.
The abstracts demonstrate the value of FORE-SIGHT Absolute Oximetry to help assess cerebral tissue oxygenation levels in a variety of clinical applications including carotid endarterectomy, orthopedic and spinal surgeries, and during cardiac arrest. Researchers showed how cerebral tissue oxygenation can be compromised in these various clinical settings and the importance of monitoring this parameter.
Robert Kopotic, Senior Director of Clinical Affairs of CASMED, stated, "Worldwide research continues to demonstrate the efficacy and utility of FORE-SIGHT technology to monitor cerebral tissue oxygenation in a range of clinical situations. It is our intent to promote cerebral oximetry as a standard of care during surgery, and to make evident the superiority of our FORE-SIGHT absolute oximetry technology in the marketplace."
Abstracts
Phenylepherine Bolus Given to Treat Hypotension Decreases Cerebral Oxygen Saturation. William P. Henick, D.O., Donald M. Mathews, M.D., Asha Mellor, M.A., Neal T. Reich, M.D., George G. Neuman, M.D., Department of Anesthesiology, St. Vincent's Catholic Medical Center, New York, NY. (ASA #A396)
Non-Invasive Absolute Cerebral Oximetry and Intraluminal Shunting during Carotid Endarterectomy. Stephanie DeNaeyer, M.D., Cathy S. DeDeyne, M.D., Ph.D., Kevin Lathouwers, M.D., Veerle De Sloovere, M.D. Rene Heylen, M.D., Ph.D., Department of Anesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine, Hasselt University, Hasselt, Belgium. (ASA #A398, SNACC #34)
Non-Invasive Absolute Cerebral Oximetry during Inhalational Anesthesia in Young Children. Kevin Lathouwers, M.D., Cathy S. DeDeyne, M.D., Ph.D., Frank Jans, M.D., Ph.D., Veerle De Sloovere, M.D., Rene Heylen, M.D., Ph.D., Department of Anesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine, University Hasselt, Hasselt, Belgium. (ASA #A939, SNACC #77)
Decrease of Cerebral Oxygen Saturation in Prone Position during Spine Surgery Measured by Absolute Cerebral Oximetry. Thomas M. Hemmerling, M.D., Lingshan Tang, M.D., Erik Arbeid, M.D., Cedrick Zaouter, M.D., Department of Anesthesiology, McGill University, Institut de Genie Biomedical, Universite de Montreal, Montreal, Canada. (ASA #LB07)
The Effect of Anesthetic Technique on Cerebral Oxygenation in the Beach Chair Position. Menachem M. Weiner, M.D., Gregory W. Fischer, M.D., Toni M. Torillo, M.D., Hung-Mo Lin, Ph.D., Meg A. Rosenblatt, M.D., Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY. (ASA #A1532)
Beach Chair Positioning Results in Significantly Lower Cerebral Oxygen Saturations. Francis DeBurghgraeve, M.D., Cathy S. DeDeyne, M.D., Ph.D., Veerle DeSloovere, M.D., Frank Jans, M.D., Ph.D., Rene Heylen, M.D., Ph.D., Department of Anesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine, Hasselt University, Hasselt, Belgium. (ASA #A1686, SNACC #35)
Non-Invasive Cerebral Oxygenation Saturation during Beach Chair Positioning in Healthy Volunteers. Joris Vundelinckx, M.D., Veerle De Sloovere, M.D., Dimitri Dylst, M.D., Rene Heylen, M.D., Ph.D., Cathy S. DeDeyne, M.D., Ph.D., Department of Anesthesiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine, Hasselt University, Hasselt, Belgium. (ASA #A1688)
Monitoring of Cerebrovascular Reactivity (by CO2 Challenge) by Non-Invasive Absolute Cerebral Oxygen Saturation (FORE-SIGHT Technology). Veerle De Sloovere, M.D., Ziekenhuis Oost-Limburg, Genk, Belgium. (SNACC #80)
New Technology of Non-Invasive Cerebral Oximetry (FORE-SIGHT Technology) to Monitor Cerebral Perfusion during Resuscitation from Cardiac Arrest (CPR). Kevin Lathouwers, M.D., Ziekenhuis Oost-Limburg, Genk, Belgium. (SNACC #81)
About CASMED® - Monitoring What's Vital
CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the first cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.
The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter, the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.
For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com.
The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders and competitors and other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.